Financial Performance Summary

Alembic Pharmaceuticals Limited reported unaudited consolidated financial results for the first quarter ended 30th June 2026 (Q1 FY27).

Key Financial Metrics:

  • Revenue from operations increased by 26% YoY to ₹2,150 Crore
  • Profit After Tax (PAT) reached ₹173 Crore, up 12% YoY
  • EBITDA pre R&D increased to ₹523 Crore
  • EBITDA pre R&D margin stood at 24%

Segment-wise Performance

India Branded Business:

  • Delivered 7% YoY growth, reaching ₹642 Crore in revenue
  • Gynaecology, Gastrology and Ophthalmology segments showed robust growth
  • Animal healthcare segment delivered encouraging performance
  • 3 new products were introduced during the quarter

International Business:

  • US Formulations grew by 49% YoY to ₹778 Crore
  • 7 product launches in the US market during the quarter
  • Ex-US Generics grew by 17% YoY to ₹383 Crore
  • Received 10 ANDA approvals during the quarter

API Business:

  • API business grew by 33% YoY to ₹346 Crore

Revenue Breakdown Table

| Particulars | Q1 FY26 (₹ Cr) | Q1 FY27 (₹ Cr) | % Change |

| India Formulations | 599 | 642 | 7% |

| USA Formulations | 523 | 778 | 49% |

| Ex-US Generics | 328 | 383 | 17% |

| API | 261 | 346 | 33% |

| Total | 1,711 | 2,150 | 26% |

Management Commentary

Mr. Pranav Amin, Managing Director, commented: "We have started FY27 on a strong note, delivering broad-based growth across our businesses. Performance during the quarter was driven by healthy volume growth, successful new product launches and continued execution across key markets. The US business delivered strong momentum, and the rest of the markets also recorded steady growth. We remain focused on strengthening our product portfolio, advancing our pipeline and driving sustainable long-term growth."

Investor Communication

The company will host an investor call at 5.30 pm IST on August 04, 2026, where senior management will discuss the company's performance and answer questions. The dial-in numbers are +91 22 6280 1411 and +91 22 7115 8312.

Company Background

Alembic Pharmaceuticals Limited is a vertically integrated research and development pharmaceutical company that has been operating since 1907. The company manufactures and markets generic pharmaceutical products worldwide and is one of the leaders in branded generics in India. The company's research and manufacturing facilities are approved by regulatory authorities including the US FDA.